AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 296 min read$IART

INTEGRA LIFESCIENCES HOLDINGS CORP (IART): Results of Operations and Financial Condition

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-q22026earningsrelease.htm EX-99.1 Document News Release Integra LifeSciences Reports Second Quarter 2026 Financial Results PRINCETON, N.J., July 29, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today

Original reporting
SEC EDGAR 8-K
Published Jul 29, 2026, 10:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 10:40 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$IART
Neutral
medium confidence
Mentioned
$IART
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IARTNeutralMed
01

Why it matters

Traders can update models for Q3 reported revenue and adjusted EPS based on the new ranges, and reassess execution risk for the planned fourth-quarter SurgiMend relaunch tied to the Braintree manufacturing ramp.

02

Market read

Fresh quarterly financials plus updated Q3 and full-year reported revenue ranges (FX-driven) and reaffirmed organic growth and adjusted EPS guidance create actionable inputs for near-term positioning.

03

What to watch

Net debt of $1.6B and 4.1x leverage could constrain flexibility; also tissue reconstruction declined organically in Q2 despite some product relaunch momentum.

Relevance 7/10Novelty 7/10Timing: ahead of/around the scheduled Q2 earnings call on July 29, 2026

Background

This is an SEC 8-K with Integra’s Q2 2026 results and forward guidance, including an FX-related update to reported revenue outlook and reaffirmation of organic growth and adjusted EPS targets.

Company-level read

Ticker impact

$IARTNeutralMedium confidence
Context

Integra reported Q2 results and updated 2026 reported revenue guidance to $1.654B-$1.695B due to a stronger U.S. dollar.

Expected impact

Near-term trading bias likely modest, with attention on whether Braintree ramp and SurgiMend relaunch timing reduces execution risk.

Evidence & confidence

The filing provides fresh quarterly datapoints (GAAP/adjusted EPS, margins, cash flow) plus a specific guidance revision tied to FX, and reiterates organic growth and adjusted EPS targets.

Market effects

Sector

Medical technology peers may see read-across on surgical product relaunch execution and supply reliability improvements, but this is company-specific.

Regional

FX sensitivity in reported revenue guidance highlights translation effects for multinational med-tech reporting.

Global

Limited broader impact; primarily affects sentiment around Integra’s specialty surgery and tissue reconstruction franchises.

Counterpoint

What could challenge this read

Because the reported revenue guidance change is explicitly FX-driven, the market may discount it and instead penalize any signs of continued tissue reconstruction weakness or leverage concerns.

Key entities

  • company
    Integra LifeSciences Holdings Corporation

    Nasdaq-listed medical technology company reporting Q2 2026 results, updating 2026 reported revenue guidance for FX, and reaffirming organic growth and adjusted EPS guidance.

  • product
    SurgiMend

    Tissue reconstruction product Integra plans to relaunch in the fourth quarter, supported by Braintree manufacturing production ramp.

  • operations
    Braintree manufacturing facility

    Facility where Integra initiated production and is ramping to support the SurgiMend relaunch.

Read at source← All news

Related articles

AUG 5
$IARTMed

Read Analyst Questions From Integra LifeSciences’s Q2 Earnings Call

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, roughly flat year over year and slightly above estimates, with adjusted EPS of $0.56 vs $0.48 expected. Management cited reimbursement pressures and product mix for margin compression, while adjusted EPS outperformance reflected execution and tariff dynamics. Full-year revenue guidance was reconfirmed at $1.67B midpoint and adjusted EPS at $2.45.

financialcontent.com4 min
AUG 1
$IARTMed

IART Q2 Deep Dive: Flat Revenue, Margin Pressure, and Operational Realignment Shape Outlook

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, flat YoY and slightly above estimates, with adjusted EPS of $0.56 (vs $0.48) and adjusted EBITDA of $78.41M. Operating margin fell to 4.6%. The company reconfirmed FY revenue guidance of $1.67B and adjusted EPS of $2.45, citing cost savings and operational realignment amid reimbursement and competitive pressures.

finance.yahoo.com6 min
JUL 30
$IARTMedAI 8/10

Integra LifeSciences Q2 Earnings Call Highlights

Knight said Integra retained its full-year EPS outlook because it has adjusted its tariff assumptions and expects higher interest expense in the second half tied to a potential refinancing of bank debt. The company still estimates its total tariff exposure for the year at about $0.10 per share. "We do not expect any operational headwinds to offset some of the upside that we saw, but we do expect to see interest expense headwinds," Knight said.

yahoo.com6 min
JUL 29
$IARTMedAI 8/10

Why Integra LifeSciences (IART) Shares Are Sliding Today

Integra LifeSciences (IART) shares fell 10.1% after Q2 results. The company reported adjusted EPS of $0.56 above estimates, but revenue was flat at $418.8 million and operating margin fell to 4.6% from 7.9%. Q3 revenue guidance was about $417.5 million, and full-year revenue guidance was reconfirmed.

financialcontent.com6 min
JUL 29
$IARTMed

Integra LifeSciences Swings To Profit In Q2; Trims FY26 Revenue Outlook

Integra LifeSciences (IART) reported Q2 net earnings of $4.48 million, or $0.06 per share, versus a year-ago net loss. Adjusted EPS was $0.56. Revenue rose 0.8% to $418.76 million. For Q3, it expects adjusted EPS of $0.53-$0.61 on $410-$425 million revenue. For FY26, it trimmed revenue guidance to $1.654-$1.695 billion and reiterated adjusted EPS of $2.40-$2.50.

rttnews.com3 min